Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241214 · ClinicalTrials.gov registry record · Phase 2
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
A Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 579
- Enrollment target
- 7
- Study locations
NCT01241214 is a Phase 2 study of Seasonal Allergic Rhinitis that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 579 participants, roughly in line with the 632-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The trial reports 7 study locations across 1 state.
The verdict
NCT01241214, a Phase 2 study of Seasonal Allergic Rhinitis, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 579 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cetirizine
- DRUG ACT-129968
Study Locations (7)
Texas
- Clinical Investigative Site 7905 - Austin
- Clinical Investigative Site 7907 - Kerrville
- Clinical Investigative Site 7903 - New Braunfels
- Clinical Investigative Site 7901 - San Antonio
- Clinical Investigative Site 7902 - San Antonio
- Clinical Investigative Site 7904 - San Antonio
- Clinical Investigative Site 7906 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241214
The ClinicalTrials.gov registry entry for NCT01241214 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 632-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01241214 reports 7 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01241214 about?
NCT01241214 is a clinical study titled "Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis". This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
What is the current status of trial NCT01241214?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 579 participants. The study started on 2010-11. Estimated completion is 2011-02.
What conditions does trial NCT01241214 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT01241214?
The interventions under investigation include: Placebo (DRUG), Cetirizine (DRUG), ACT-129968 (DRUG).
Who is sponsoring clinical trial NCT01241214?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01241214 being conducted?
This trial has 7 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
-
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
COMPLETED · Phase 2
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.